Novartis Medical’s Post

Medications are powerful tools, and a pharmacist's job is to use them safely and effectively." #EmpoweringPharmacists #HealthierFuture #PharmacyInnovation2024 #InternationalPharmacyWeek #SwalifeBiotech #InternationalPharmacyWeek2024 #InternationalPharmacovigilanceWeek2024

The most concerning factor in Oncology field

Meet the Prescient team at #ASCO2024 to discuss the latest trends in oncology drug development and patient care! Connect directly with Benjamin Doran, Vice President; Swati Anand Kkatyal, Global Head of Insights; Rouzbeh Ahmadian, MD, MS, MBA, Vice President; Dr. Laura M. Darnieder, Director; Conrad Tenenbaum, Ph.D., Director; Lee Griffiths, Director; and Dr Debasish Talukdar, CEO, to learn more about our offerings and how we can help you. #Oncology #Hematology #ClinicalTrials #HealthTechnology #GlobalAccess #OncologyResearch

In this article, Precision Medicine Online provides an overview of the findings from an ICON survey of oncology research professionals including insights on how precision medicine approaches are changing development strategies and the extent these therapeutic advances will benefit patients in the future. https://ow.ly/V6J950TqGSj

Discover more from #ASCO24! 🌟 Dr Jia (Jenny) Liu shared insights with Video Journal of Oncology (VJOncology) on Starpharma’s promising Phase 1/2 clinical trial of DEP SN38 (DEP irinotecan). The trial results, highlighted during an oral podium presentation at the 2024 ASCO Annual Meeting, showed promising anti-cancer efficacy and tolerability in very late-stage patients who were heavily pre-treated. Watch it on VJ Oncology. 📺 #CancerResearch #ClinicalTrials #Oncology #Starpharma

NEW from #ASCO2024 | Enhancing delivery of #chemotherapies with dendrimer nanoparticles 🎥 🇺🇸 Jia (Jenny) Liu, MD, PhD, St Vincent’s Hospital, comments on how #dendrimernanoparticles can improve the delivery of #chemotherapy to patients The size of the #nanoparticle can reduce off target #toxicity and prevent the drug being metabolized in the liver, reducing the severity of adverse events in patients 🔦 Learn more 👉 https://lnkd.in/e3uf7UzH #VJOncology #Oncologynews American Society of Clinical Oncology (ASCO)

The Scientific Program Committee and American Society of Clinical Oncology (ASCO) Leadership selected our Trials in Progress abstract for presentation in a poster session! Meet our team to discuss our ongoing clinical trial. Date and Time: Saturday, June 1, 9:00 AM - 12:00 PM Abstract Number: TPS3171 Abstract Title: A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of TT125-802 in patients with advanced solid tumors. #ASCO24 #StoppingCancerDrugResistance

We are officially kicking off #ESMO24 today! Looking forward to inspiring talks and discussions on all the brand new data that will be shared during this congress! #teamBayer #prostatecancer

#HER2DX and its impact on therapeutic #decisionmaking   Understanding its credibility, and clinical relevance is crucial for optimizing treatment strategies and enhancing patient outcomes in the context of #HER2+ #breastcancer in Clinical and Translational Oncology Read it here 👉🏻https://ow.ly/YbVo50RnSp6

Important basics to master especially if you're working in oncology studies.